142 related articles for article (PubMed ID: 38331394)
21. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.
Speiser JL; Ambrosius WT; Pajewski NM
Clin Trials; 2023 Oct; 20(5):507-516. PubMed ID: 37243355
[TBL] [Abstract][Full Text] [Related]
22. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A).
Nakamura K; Shibata T; Takashima A; Yamamoto S; Fukuda H
Jpn J Clin Oncol; 2012 Oct; 42(10):896-902. PubMed ID: 22844128
[TBL] [Abstract][Full Text] [Related]
24. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
[TBL] [Abstract][Full Text] [Related]
25. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).
Lengliné E; Baba J; de Boissieu P; Beaufils A; Desbiolles A; Diatta T; Cochat P; Chevret S
Eur J Cancer; 2024 Jun; 204():114047. PubMed ID: 38653034
[TBL] [Abstract][Full Text] [Related]
26. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
27. Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpoint.
Zhou H; Sun L; Wang M
Contemp Clin Trials; 2023 Jun; 129():107200. PubMed ID: 37068588
[TBL] [Abstract][Full Text] [Related]
28. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020.
Sherry AD; Hahn AW; McCaw ZR; Abi Jaoude J; Kouzy R; Lin TA; Minsky B; Fuller CD; Meirson T; Msaouel P; Ludmir EB
JAMA Netw Open; 2024 Mar; 7(3):e243379. PubMed ID: 38546648
[TBL] [Abstract][Full Text] [Related]
29. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
30. Adjusting overall survival for treatment switches: commonly used methods and practical application.
Watkins C; Huang X; Latimer N; Tang Y; Wright EJ
Pharm Stat; 2013; 12(6):348-57. PubMed ID: 24136868
[TBL] [Abstract][Full Text] [Related]
31. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
32. Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis.
Tang RS; Zhu J; Chen TT; Liu F; Jiang X; Huang B; Lee JJ; Beckman RA
Contemp Clin Trials; 2022 May; 116():106736. PubMed ID: 35331946
[TBL] [Abstract][Full Text] [Related]
33. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
Ray ME; Bae K; Hussain MH; Hanks GE; Shipley WU; Sandler HM
J Natl Cancer Inst; 2009 Feb; 101(4):228-36. PubMed ID: 19211454
[TBL] [Abstract][Full Text] [Related]
34. Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study.
Zhang Y; Chen D; Cheng S; Liang Z; Yang L; Li Q; Bai L; Li H; Liu W; Shi L; Guan X
PLoS Med; 2023 Dec; 20(12):e1004319. PubMed ID: 38085706
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.
Texier M; Rotolo F; Ducreux M; Bouché O; Pignon JP; Michiels S
Comput Math Methods Med; 2018; 2018():1672176. PubMed ID: 29568321
[TBL] [Abstract][Full Text] [Related]
36. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
Denne JS; Stone AM; Bailey-Iacona R; Chen TT
J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
[TBL] [Abstract][Full Text] [Related]
37. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group.
Kumar A; Soares H; Wells R; Clarke M; Hozo I; Bleyer A; Reaman G; Chalmers I; Djulbegovic B;
BMJ; 2005 Dec; 331(7528):1295. PubMed ID: 16299015
[TBL] [Abstract][Full Text] [Related]
38. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
39. Consistency of phase III clinical trial abstracts presented at an annual meeting of the American Society of Clinical Oncology compared with their subsequent full-text publications.
Tam VC; Hotte SJ
J Clin Oncol; 2008 May; 26(13):2205-11. PubMed ID: 18445846
[TBL] [Abstract][Full Text] [Related]
40. Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules.
Eaton AA; Zabor EC
Stat Med; 2022 Apr; 41(9):1599-1612. PubMed ID: 35043427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
